Epicentrx,

EpicentRx is an innovation-driven clinical-stage drug and device company that puts the emphasis on “ease” - ease of treatment, ease of side effects, and ease of symptoms during the treatment of a range of diseases including lung cancer, and head and neck cancer, and different inflammatory disorders for which the company has received several grants and orphan designations. The lead device is called the eLOOP and the lead therapies are the direct NLRP3 inhibitor, nibrozetone (RRx-001), and the TGF-β trap-enhanced oncolytic adenovirus, AdAPT-001, in Phase 3, and Phase 2 clinical trials, respectively.